Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,039JPY
2:00am EDT
Change (% chg)

¥-13 (-0.63%)
Prev Close
¥2,052
Open
¥2,050
Day's High
¥2,050
Day's Low
¥2,010
Volume
918,500
Avg. Vol
1,557,852
52-wk High
¥2,054
52-wk Low
¥1,397

Chart for

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Japan segment manufactures and sells ethical and general use drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other... (more)

Overall

Beta: 0.57
Market Cap(Mil.): ¥816,491.12
Shares Outstanding(Mil.): 397.90
Dividend: 9.00
Yield (%): 0.88

Financials

  4506.T Industry Sector
P/E (TTM): 16.30 29.67 32.21
EPS (TTM): 125.88 -- --
ROI: 8.51 13.44 13.05
ROE: 10.10 15.16 14.90

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

Feb 26 2018

BRIEF-Sumitomo Dainippon Pharma says change of president

* Says it appoints Masayo Tada as chairman of the board, and Hiroshi Nomura as president, effective April 1

Feb 23 2018

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

Feb 16 2018

BRIEF-Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.

* Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC regarding their submissions of Abbreviated New Drug Applications for generic copies of LATUDA®(lurasidone HCl tablets)

Feb 14 2018

BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film

* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes)

Jan 29 2018

BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan

* POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN

Dec 27 2017

BRIEF-Sumitomo Dainippon Pharma says result of early-retirement program

* Says 86 employees took up the offer of the early-retirement program announced on Sept. 27

Dec 24 2017

BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD

* SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD

Dec 05 2017

BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

* Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co

Nov 21 2017

BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin

* Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries

Oct 30 2017

Earnings vs. Estimates